Brand Name

Xeljanz

Generic Name
Tofacitinib
View Brand Information
FDA approval date: November 08, 2012
Classification: Janus Kinase Inhibitor
Form: Tablet, Solution

What is Xeljanz (Tofacitinib)?

XELJANZ and XELJANZ XR are Janus kinase inhibitors. XELJANZ tablets and XELJANZ XR are indicated for the treatment of adult patients with: Moderately to severely active rheumatoid arthritis , who have had an inadequate response or intolerance to one or more TNF blockers., Active psoriatic arthritis , who have had an inadequate response or intolerance to one or more TNF blockers., Active ankylosing spondylitis , who have had an inadequate response or intolerance to one or more TNF blockers., Moderately to severely active ulcerative colitis , who have had an inadequate response or intolerance to one or more TNF blockers. XELJANZ are indicated for the treatment of pediatric patients 2 years of age and older with:, Active PsA, who have had an inadequate response or intolerance to one or more TNF blockers., Active polyarticular course juvenile idiopathic arthritis , who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use :, Use of XELJANZ/XELJANZ XR for RA, AS, PsA, or pcJIA in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Disease Phase IIa Open-Label Clinical Trial and Associated Mechanistic Studies

Background: Sjogren disease is an autoimmune disease - that is, a disease that causes the body's immune system to attack its own organs and tissues. Sjogren disease can affect the kidneys, lungs, or other organs. It can also cause dry mouth and eyes, fever, joint pain, rashes, and other symptoms. Researchers want to know if a drug approved to treat rheumatoid arthritis and other autoimmune diseases can help p...

Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response

Summary: Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure. Current treatment goals are to minimize pain, limit joint damage, and prevent loss of function. Drugs used to treat RA include non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids, and disease-modifying anti-rheumatic drugs (DMARDs), including biologics...

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica - JADORE-BARI Study

Summary: Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease affecting the elderly. The diagnosis is based on established ACR/EULAR classification criteria. The activity of the disease is evaluated using the PMR-AS, a disease activity score based on morning stiffness, ability to elevate the upper limbs, physician's global disease assessment and pain assessment measured by the patient using VAS...